&lt;&lt;insert slide 1; Chapter Title: Introduction; 00:00 &gt;&gt;  
<h3> VTE in Cancer: What Do the Latest Data Suggest?</h3>
&lt;&lt;insert slide 2; Chapter Title: Cancer and VTE Risk; 00:52 &gt;&gt;  
<h3> Risk of Cancer-Associated VTE<sup type="ref">[1-4]</sup></h3> 
<ul><li>	Risk of venous thromboembolism (VTE) is elevated in cancer</li>
<li>	In general, patients with cancer have a 1:5 chance of developing VTE</li>
<li>	VTE risk is variable and dependent on a number of factors, including
<ul><li>	Cancer type (site of tumor)</li>
<li>	Cancer stage</li>
<li>	Time since diagnosis of cancer</li>
<li>	Cancer treatment</li></ul></li>
</ul>
&lt;&lt;insert slide 3: 01:12 &gt;&gt;  
<h3> Risk Factors for Cancer-Associated VTE: Cancer Site<sup type="ref">[4]</sup></h3> 
<ul><li>	The predominant risk factor is the location of the primary tumor</li>
<li>	Overall, gastrointestinal (GI), pancreas, brain, lung, and ovarian cancer induce the highest risks</li>
<li>	Relatively lower risks are seen in patients with breast or prostate cancer</li>
</ul>
&lt;&lt;insert slide 4: 02:27 &gt;&gt;  
<h3> Risk Factors for Cancer-Associated VTE: Cancer Treatment Modality<sup type="ref">[5]</sup></h3> 
&lt;&lt;insert slide 5: 04:25 &gt;&gt;  
<h3> Risk Factors for Cancer-Associated VTE: Patient-Related Factors<sup type="ref">[5]</sup></h3> 
<ul><li>	Ethnicity
<ul><li>	Risk greater with African American vs Caucasian vs Asian population</li>
<li>	Attributed risk, however, is minor</li></ul></li>
<li>	Compression of major vessels by tumors</li>
</ul>
&lt;&lt;insert slide 6; Chapter Title: LMWH for VTE Treatment; 05:18 &gt;&gt;  
<h3> Guideline Recommendations: Cancer-Associated VTE Treatment<sup type="ref">[6-8]</sup></h3> 
<ul><li>	Most guidelines recommend monotherapy with low-molecular-weight heparin (LMWH) for at least 6 months</li>
<li>	Latest data from VTE treatment trials with non-vitamin K antagonist oral anticoagulants (NOACs) are challenging the current treatment paradigm</li>
</ul>
&lt;&lt;insert slide 7: 06:54 &gt;&gt;  
<h3> Challenges With LMWH</h3>
<ul><li>	LMWHs are injectable agents
<ul><li>	Injectable agents are treated differently in prescription plans and copayment can be high</li>
<li>	Daily self-injection adds to the burden of treatment</li></ul></li>
</ul>
&lt;&lt;insert slide 8: 07:32 &gt;&gt;  
<h3> Persistence With Anticoagulation for Cancer-Associated VTE<sup type="ref">[9]</sup></h3> 
<ul><li>	Real-world analysis: LMWH was associated with significantly lower persistence and shorter duration of treatment</li>
</ul>
&lt;&lt;insert slide 9: 08:33 &gt;&gt;  
<h3> VTE and Major Bleeding Risk in Patients Receiving Chemotherapy: A Real-World Analysis<sup type="ref">[10]</sup></h3> 
<ul><li>	Patients with cancer are at high risk of both VTE and major bleeding</li>
<li>	VTE and major bleeding can be fatal</li>
<li>	Major bleeding can be difficult to treat; especially GI mucosal bleeding</li>
<li>	Minor (eg, nuisance) bleeding is also common</li>
</ul>
&lt;&lt;insert slide 10; Chapter Title: NOACS for VTE Treatment; 09:24 &gt;&gt;  
<h3> Treatment of Cancer-Associated VTE: Clinical Trials of NOACs<sup type="ref">[11-13]</sup></h3> 
&lt;&lt;insert slide 11: 10:36 &gt;&gt;  
<h3> Hokusai VTE-Cancer: Design<sup type="ref">[14]</sup></h3> 
<ul><li>	Study population with active cancer and symptomatic/incidental deep vein thrombosis (DVT) or proximal pulmonary embolism (PE)
<ul><li>	DVT of proximal lower extremity (popliteal, femoral, or iliac vein thrombosis)</li>
<li>	PE involving segmental or more proximal pulmonary arteries</li></ul></li>
<li>	All patients were treated for at least 6 months</li>
<li>	Physicians were encouraged to continue treatment for 12 months</li>
</ul>
&lt;&lt;insert slide 12: 11:45 &gt;&gt;  
<h3> Hokusai VTE-Cancer: Primary Outcome<sup type="ref">[11]</sup></h3> 
<ul><li>	Edoxaban was noninferior to dalteparin</li>
</ul>
&lt;&lt;insert slide 13: 12:05 &gt;&gt;  
<h3> Hokusai VTE-Cancer: Primary Outcome Components<sup type="ref">[11]</sup></h3> 
<ul><li>	Rate of recurrent VTE was significantly lower with edoxaban vs dalteparin</li>
<li>	Rate of major bleeding was significantly higher with edoxaban vs dalteparin</li>
<li>	Most major bleeding occurred in patients with GI cancers</li>
</ul>
&lt;&lt;insert slide 14: 13:11 &gt;&gt;  
<h3> SELECT-D: Design<sup type="ref">[15]</sup></h3> 
<ul><li>	Study population similar to Hokusai VTE-Cancer</li>
</ul>
&lt;&lt;insert slide 15: 13:37 &gt;&gt;  
<h3> SELECT-D: Primary Endpoint &#8211; Recurrent VTE at 6 Months<sup type="ref">[12]</sup></h3> 
<ul><li>	Rivaroxaban was associated with relatively low VTE recurrence compared with dalteparin</li>
</ul>
&lt;&lt;insert slide 16: 13:48 &gt;&gt;  
<h3> SELECT-D: Major and CRNM Bleeding at 6 Months<sup type="ref">[12]</sup></h3> 
<ul><li>	Rivaroxaban was associated with relatively higher clinically relevant nonmajor (CRNM) bleeding compared with dalteparin</li>
<li>	Most of the major bleeding occurred in patients with GI cancers</li>
</ul>
&lt;&lt;insert slide 17: 15:01 &gt;&gt;  
<h3> SELECT-D: Major Bleeding by Tumor Type<sup type="ref">[12]</sup></h3> 
<ul><li>	Among GI cancers, most major bleeding was confined to upper GI cancers</li>
</ul>
&lt;&lt;insert slide 18: 15:28 &gt;&gt;  
<h3> Hokusai VTE-Cancer: Major Bleeding by Tumor Type<sup type="ref">[16]</sup></h3> 
<ul><li>	Excess major bleeding with edoxaban was confined to patients with GI cancer</li>
</ul>
&lt;&lt;insert slide 19; Chapter Title: Guidance on Use of NOACs; 16:38 &gt;&gt;
<h3> NOACs for Treatment of Cancer Associated VTE: Guidance From ISTH<sup type="ref">[17]</sup></h3> 
<ul><li>	An estimated 60% to 70% of overall cancer population may be eligible for treatment with NOACs</li>
<li>	In patients with high risk of bleeding, reassess therapy options when bleeding risk changes over time</li>
<li>	Patients with severe thrombocytopenia are candidates for LMWH
<ul><li>	LMWH can be dose-adjusted based on the platelet count</li>
<li>	Fine tuning of dose is not currently possible with NOACs</li></ul></li>
</ul>
&lt;&lt;insert slide 20: 18:55 &gt;&gt;  
<h3> Anticoagulation in Cancer Patients With Thrombocytopenia: Guidance From ISTH<sup type="ref">[18]</sup></h3> 
<ul><li>	Option to start with one therapy and switch to another when patient condition improves</li>
<li>	For example, in patients with GI cancer
<ul><li>	Could start therapy with LMWH</li>
<li>	If bleeding risk improves, switch to a NOAC</li>
<li>	If platelet count declines after switching to NOAC, bridge to LMWH until platelet count improves to safely resume NOAC</li></ul></li>
</ul>
&lt;&lt;insert slide 21; Chapter Title: VTE Prevention; 22:33 &gt;&gt;
<h3> Guidance for Prevention of Cancer-Associated VTE<sup type="ref">[19]</sup></h3> 
<ul><li>	Clinical trials on thromboprophylaxis found benefit in patients with high risk score (Khorana score &#8805;3)</li>
<li>	Although thromboprophylaxis is recommended in patients with cancer who are at high risk of VTE, it is not usually followed</li>
</ul>
&lt;&lt;insert slide 22: 23:30 &gt;&gt;  
<h3> CASSINI: Design<sup type="ref">[20]</sup></h3> 
&lt;&lt;insert slide 23: 24:07 &gt;&gt;  
<h3> AVERT: Design<sup type="ref">[21]</sup></h3> 
&lt;&lt;insert slide 24; Chapter Title: Summary; 24:50 &gt;&gt;
<h3> Summary</h3>
&lt;&lt;insert slide 25: 25:36 &gt;&gt;  
<h3> Summary (cont)</h3>
&lt;&lt;insert slide 26: 27:04 &gt;&gt;  
<h3> Thank you</h3>